tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

BMRN Stock Latest News

BioMarin Pharmaceutical Approves Equity Plan Amendment
Company AnnouncementsBioMarin Pharmaceutical Approves Equity Plan Amendment
2d ago
8K
BMRN
Strategic Acquisition of Inozyme Boosts BioMarin’s Long-Term Revenue Prospects
PremiumRatings
Strategic Acquisition of Inozyme Boosts BioMarin’s Long-Term Revenue Prospects
5d ago
BMRN
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
5d ago
ACAD
AFMD
Strategic Acquisition of INZY Boosts BioMarin’s Growth Potential and Pipeline Expansion
PremiumRatings
Strategic Acquisition of INZY Boosts BioMarin’s Growth Potential and Pipeline Expansion
5d ago
BMRN
BioMarin’s Strategic Acquisition of Inozyme Boosts Growth Prospects and Stock Price Target
PremiumRatings
BioMarin’s Strategic Acquisition of Inozyme Boosts Growth Prospects and Stock Price Target
6d ago
BMRN
BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges
PremiumRatingsBioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges
8d ago
BMRN
Leerink bullish on BioMarin following Inozyme deal, expects additional BD
Premium
The Fly
Leerink bullish on BioMarin following Inozyme deal, expects additional BD
8d ago
BMRN
INZY
BioMarin Pharmaceutical’s Strategic Growth and Market Potential: A Buy Rating by Yun Zhong
Premium
Ratings
BioMarin Pharmaceutical’s Strategic Growth and Market Potential: A Buy Rating by Yun Zhong
8d ago
BMRN
BioMarin says Inozyme deal to strengthen enzyme therapies portfolio
PremiumThe Fly
BioMarin says Inozyme deal to strengthen enzyme therapies portfolio
8d ago
BMRN
INZY
BioMarin Acquires Inozyme Pharma for $270 Million
PremiumCompany Announcements
BioMarin Acquires Inozyme Pharma for $270 Million
8d ago
8K
BMRN
BioMarin’s acquisition of Inozyme to strengthen enzyme therapies portfolio
PremiumThe Fly
BioMarin’s acquisition of Inozyme to strengthen enzyme therapies portfolio
8d ago
BMRN
INZY
BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M
PremiumThe Fly
BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M
8d ago
BMRN
INZY
BioMarin reaffirms previously provided full-year 2025 financial guidance
PremiumThe FlyBioMarin reaffirms previously provided full-year 2025 financial guidance
8d ago
BMRN
BioMarin reports data from studies of Voxzogo
Premium
The Fly
BioMarin reports data from studies of Voxzogo
12d ago
BMRN
BioMarin Pharmaceuticals Reports Strong Q1 2025 Earnings
Premium
Company Announcements
BioMarin Pharmaceuticals Reports Strong Q1 2025 Earnings
22d ago
BMRN
BioMarin price target lowered to $78 from $82 at Citi
PremiumThe Fly
BioMarin price target lowered to $78 from $82 at Citi
22d ago
BMRN
BioMarin Pharmaceutical: Hold Rating Amid Strong Revenue and Cautious Outlook
PremiumRatings
BioMarin Pharmaceutical: Hold Rating Amid Strong Revenue and Cautious Outlook
23d ago
BMRN
BioMarin’s Strong Q1 2025 Performance and Growth Outlook
PremiumCompany Announcements
BioMarin’s Strong Q1 2025 Performance and Growth Outlook
23d ago
BMRN
BioMarin Pharmaceutical: Strong Financial Performance and Promising Growth Justify Buy Rating
PremiumRatings
BioMarin Pharmaceutical: Strong Financial Performance and Promising Growth Justify Buy Rating
23d ago
BMRN
BioMarin reports Q1 EPS $1.13, consensus 95c
PremiumThe FlyBioMarin reports Q1 EPS $1.13, consensus 95c
23d ago
BMRN
BioMarin sees 2025 EPS $4.20-$4.40, consensus $4.30
Premium
The Fly
BioMarin sees 2025 EPS $4.20-$4.40, consensus $4.30
23d ago
BMRN
Notable companies reporting after market close
Premium
The Fly
Notable companies reporting after market close
23d ago
SYK
XYZ

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >